Edition:
United States

Pernix Therapeutics Holdings Inc (PTX.A)

PTX.A on American Stock Exchange

2.85USD
16 Nov 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.85
Open
--
Day's High
--
Day's Low
--
Volume
90
Avg. Vol
--
52-wk High
$3.46
52-wk Low
$2.47

Chart for

About

Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as... (more)

Overall

Beta: 1.66
Market Cap(Mil.): $32.87
Shares Outstanding(Mil.): 11.53
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.18 15.80
EPS (TTM): -- -- --
ROI: -- 15.02 12.07
ROE: -- 16.37 16.02

BRIEF-Pernix Therapeutics posts Q3 revenue of $40.5 mln

* Pernix Therapeutics reports third quarter 2017 financial results

Nov 07 2017

BRIEF-Pernix Therapeutics announces sale of non-core product

* Pernix Therapeutics Holdings Inc - ‍sale of a non-core product Cedax to SI Pharmaceuticals LLC, for $2 million in gross cash proceeds​ Source text for Eikon: Further company coverage:

Nov 06 2017

BRIEF-Pernix Therapeutics says CFO and president Graham Miao resigns

* Pernix Therapeutics announces planned departure of chief financial officer

Oct 17 2017

BRIEF-Pernix Therapeutics reports qtrly net loss per common share $2.16

* Pernix Therapeutics reports second quarter 2017 financial results and provides business update

Jul 27 2017

BRIEF-Pernix Therapeutics files for resale of up to 10.1 million shares of common stock by selling stockholders - SEC filing‍​

* Pernix Therapeutics files for resale of up to 10.1 million shares of common stock by selling stockholders - SEC filing‍​ Source text: (http://bit.ly/2upc3NQ) Further company coverage:

Jul 24 2017

BRIEF-Pernix Therapeutics Holdings expects Q2 revenues to be between $33 mln and $35 mln

* Pernix Therapeutics pre-announces certain preliminary second quarter 2017 financial results

Jul 20 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $138.00 -0.87
Novartis AG (NOVN.S) CHF83.30 +0.90
Pfizer Inc. (PFE.N) $35.37 -0.19
Roche Holding Ltd. (ROG.S) CHF230.10 +1.10
Roche Holding Ltd. (RO.S) CHF233.30 +1.30
Merck & Co., Inc. (MRK.N) $55.20 +0.03

Earnings vs. Estimates